For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
500 - 600 mg per m² of body surface area (BSA)
From 500 To 600 mg per m² of body surface area (BSA) once every day
5-fluorouracil is commonly used in chemotherapy regimens in combination with cyclophosphamide and methotrexate (CMF), or epirubicin, cyclophosphamide (FEC) or methotrexate and leucovorin (MFL). The usual dose range is 500-600 mg/m² body surface as an intravenous bolus and repeated every 3–4 weeks as necessary. In adjuvant treatment of primary invasive breast cancer, duration of treatment will usually continue for 6 cycles.